Material and Method: Ischemic stroke survivors with National Institute of Health Stroke Scale (NIHSS) ≤8 were randomly allocated into four groups, receiving aspirin, clopidogrel, combined aspirin and dipyridamole, and cilostazol. The change of MPV, NIHSS, and modified Rankin Scale (mRS) were recorded at baseline and week 4 in all studied groups. MPV was measured using the standard automated blood test for complete blood count.

Results: Twenty-one subjects were included in this study. They comprised of five cases in each antiplatelet group, except for aspirin, which had six subjects. Male was 57%, and hypertension was the most common risk factor (61.9%). Most of participants (76%) had small vessel disease. At 4-week, MPV was reduced and NIHSS, mRS were improved in every studied group. Clopidogrel significantly reduced NIHSS score (p = 0.003), and it produced the greatest reduction in MPV compared to others.

Conclusion: Every type of antiplatelets included in this study reduced MPV, NIHSS, and mRS in acute non-cardioembolic stroke patients. Clopidogrel improved NIHSS the most.

Keywords: Mean platelet volume (MPV), Stroke, Antiplatelet drugs